HAE Haemonetics Corp

  1. Stocks
  2. Healthcare
  3. NYSE: HAE

Price (delayed)

$78.78

Market cap

$3.58B

P/E Ratio

38.24

Dividend/share

N/A

EPS

$2.06

Enterprise value

$4.56B

?
Relative Growth: Rel. Growth: 29
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 41
Relative Profitability: Rel. Profitability: 57

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of ...

Highlights
The company's quick ratio has surged by 86% YoY and by 58% QoQ
The company's gross margin rose by 7% YoY
The price to earnings (P/E) is 80% higher than the last 4 quarters average of 21.2 but 13% lower than the 5-year quarterly average of 43.8
HAE's net income is down by 45% since the previous quarter and by 42% year-on-year
The company's EPS fell by 44% QoQ and by 38% YoY
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.haemonetics.com
Peers: TMO SYK BDX CERS

Key stats

What are the main financial stats of HAE

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
1.78%
1 week
1.18%
1 month
8.11%
1 year
6.09%
YTD
-1.71%
QTD
5.04%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$1.33B
Gross profit
$787.59M
Operating income
$154.86M
Net income
$97.31M
Gross margin
59%
Net margin
7.3%
HAE's net income is down by 45% since the previous quarter and by 42% year-on-year
The net margin is down by 45% since the previous quarter and by 41% year-on-year
The operating margin has contracted by 33% from the previous quarter and by 21% YoY
The operating income is down by 32% since the previous quarter and by 22% year-on-year

Price vs fundamentals

How does HAE's price correlate with its fundamentals

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
HAE P/E details
P/E
38.24
P/B
4.6
P/S
2.79
EV/EBIT
29.09
EV/EBITDA
16.98
EV/Sales
3.42
The price to earnings (P/E) is 80% higher than the last 4 quarters average of 21.2 but 13% lower than the 5-year quarterly average of 43.8
The company's EPS fell by 44% QoQ and by 38% YoY
The price to book (P/B) is 31% higher than the last 4 quarters average of 3.5 and 4.5% higher than the 5-year quarterly average of 4.4
The equity has declined by 13% since the previous quarter and by 3% year-on-year
The stock's P/S is 21% more than its last 4 quarters average of 2.3 but 10% less than its 5-year quarterly average of 3.1

Efficiency

How efficient is Haemonetics business performance
The company's return on assets fell by 44% QoQ and by 40% YoY
HAE's return on equity is down by 44% since the previous quarter and by 41% year-on-year
The company's return on invested capital fell by 40% QoQ and by 23% YoY
The company's return on sales fell by 38% QoQ and by 28% YoY

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 50% more than the total liabilities
The company's quick ratio has surged by 86% YoY and by 58% QoQ
The current ratio has soared by 82% YoY and by 69% from the previous quarter
The debt is 54% greater than the equity
The debt to equity has grown by 15% from the previous quarter and by 3.4% YoY
The equity has declined by 13% since the previous quarter and by 3% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.